Phase 1/2Not yet recruiting

Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)

Sponsor
Dr David Hasan, M.D. (Academic or other)
Enrollment
82 planned
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Tirofiban; Placebo
Ages
adults, older adults
Registry
NCT07493577

Full record on ClinicalTrials.gov

From the registry

An exploratory, randomized, double-blinded, placebo-controlled, two-center clinical trial to determine the maximum tolerated dosage of intravenous tirofiban in patients with aneurysmal subarachnoid hemorrhage (aSAH) post-endovascular coiling. The study will also assess pharmacology and safety, with exploratory endpoints including delayed cerebral ischemia (DCI), vasospasm, and functional outcomes.

Primary outcomes

  • Tirofiban dosage-limiting toxicity (DLT)

History

  1. Study completion expected

  2. Primary completion expected

  3. Expected to start

  4. Last registry update

  5. Registered